Brutalist Biotech
Max
3
|
5
|
10
|
20
items per feed.
Cutting-edge Biotech news: Presented the old-fashioned way.
Fierce Biotech
GSK sees phase 3 win for Hansoh-partnered ADC in China as validating its ‘priority asset’
(20h)
Bausch + Lomb gives up on glaucoma eye drop hopeful after phase 2 fail
(23h)
ARPA-H awards up to $160M to scientists developing custom genetic medicines
(1d)
Chutes & Ladders—Idorsia locks in new CEO after shakeup
(1d)
Roche ends 2 Huntington’s disease programs, including Ionis-partnered tominersen
(1d)
BioPharma Dive
GSK, Hansoh ADC extends survival in lung cancer study
(16h)
ARPA-H puts $160M into bespoke drug therapies; Biohaven switches up scientific leadership
(20h)
Roche scraps two Ionis-partnered Huntington’s drugs
(1d)
GSK ends brain drug alliance with Alector
(1d)
HHS plan to speed drug research won’t remove ‘self-inflicted’ delays
(1d)
Endpoints News
Apnimed files for IPO as FDA reviews its sleep apnea drug
(10h)
FDA returns to releasing pharma rejection letters with 14 new CRLs
(14h)
FDA rejects Hengrui-Elevar liver cancer drug combo for third time
(14h)
FDA adds 100+ new CDER employees in a quarter for first time since late 2024
(15h)
US biotechs turn secretive as they fear competition from rising Chinese industry
(16h)
BioSpace
From sequence to scale: Gene editing’s new era in biologics manufacturing
(17h)
AAIC 2026: Tau-targeted Alzheimer’s treatments heat up while amyloid therapies persist
(17h)
GSK and Hansoh’s ADC clinches late-stage win, teeing up regulatory submission in China
(18h)
AstraZeneca, Ionis’ Wainua woes send waves across ATTR-CM space
(19h)
Roche scraps 2 Huntington’s studies, handing Ionis more bad news
(20h)
STAT News
Nominee for key federal health role has a history of questioning vaccines
(12h)
Roche ends Huntington’s gene-silencing programs
(18h)
We’re reading about bigger drug discounts in Germany, drugmakers embracing secrecy, and more
(19h)
FDA quietly pushes back deadline on electric shock ban
(20h)
How a Boston doctor built a following as a ‘loud and unafraid’ voice in the Trump era
(23h)
BioPharma Trend
Seven HealthTech Trends In Europe To Watch
(2w)
Self-Care Is Not a Product, It’s Critical Infrastructure: Why We Must Work Together to Make Health Systems Resilient.
(3w)
Ginkgo Datapoints, Tangible Scientific, and Inductive Bio launch ADME-One, a packaged ADME service for hit identification
(1mo)
AI Won't Replace Clinical Programmers. It Will Split Them Into Two Groups.
(2mo)
Novo Nordisk and OpenAI Team Up to Integrate AI from Discovery to Supply Chain
(2mo)
Drug Channels
When Access Tightens, Prior Authorization Execution Becomes the Differentiator
(21h)
The Hidden Cost of 340B for Employers and Health Plans
(2d)
The Hidden Cost of 340B for Employers and Health Plans
(2d)
Drug Channels News Roundup, June 2026: PBM Shakeout Accelerates, 340B Enters a New Era, Rebate Questions Persist, Mark Cuban Wins Again, and Ge Bai’s HHS Nomination
(2w)
Drug Channels News Roundup, June 2026: PBM Shakeout Accelerates, 340B Enters a New Era, Rebate Questions Persist, Mark Cuban Wins Again, and Ge Bai’s HHS Nomination
(2w)
European Biotechnology Magazine
Roche drops two Huntington’s programmes from Ionis
(23h)
AstraZeneca and Ionis miss in key ATTR-CM trial
(1d)
GSK ends Alector neuroscience deal after trial failures
(1d)
Alchemab extends Series A with £25m from British Business Bank
(2d)
AZ buys ex-China rights to Sino’s COPD drug for $2.1bn
(2d)
Drug Hunter
How to “pHLIP” the Script on Drug Delivery
(17h)
ACT-1004-1239
(1d)
TERN-701
(2d)
Getting Large Molecules Into the Brain Through Transferrin Receptor-Mediated Delivery
(3d)
sparsentan
(4d)
Labiotech.EU
Top biotech deals in June 2026
(18h)
Turning cancer cell dependencies into targeted therapies
(1d)
11 biotech companies leading the way in Denmark
(2d)
The hidden innovation system behind drug repurposing
(3d)
Why Customer Experience Centers are becoming practical infrastructure for life sciences innovation in Europe
(4d)
Bio IT World
Signal Management Isn’t Broken; It Simply Belongs to a Previous Era
(1d)
Network Effects: John Quackenbush on How Networks Illuminate Biology Beyond Gene Expression
(2d)
Insilico Medicine Launches Phase III Trial for AI-Developed Drug
(3d)
Digital Brain Twin Tailor-Made for Autism Spectrum Disorder
(4d)
Follow the Money: Inflammatory Bowel Disease Oral Drug, Breast, Colorectal Cancer ADCs, Other Next-Gen, Novel Treatments
(1w)
GEN News
Macrophage Membrane-Derived Nanoparticles Shows Potential Against Candida Infections
(15h)
Epigenomic Analysis Uncovers New AML Subgroups and Drug Sensitivities
(1d)
Stem Cell Therapy Shows Promise in First Human Parkinson’s Disease Trial
(1d)
Crohn’s Disease Phage Therapy Neutralizes Inflammatory E. coli in Mouse Model
(1d)
Engineered AAVs Harness Glymphatic System to Reach Brain Targets in Mice
(1d)
Cure Today
A Simple Calf, Hamstring & Low Back Relief Routine for Patients With Cancer
(2d)
What Patients Should Know About Preparing for Cell Therapy
(2d)
Targeted therapy in Lung Cancer Care: What the Research Shows
(2d)
What the 2026 World Cup Teaches About Hope, Resilience, and Recovery
(2d)
Rob Lowe: Clinical Trials Extended My Grandmother's Life
(3d)
Contract Pharma
The Friday Brief for July 10, 2026: Companies and Facilities Changing Hands
(18h)
Biohaven Announces Scientific Leadership Changes
(19h)
Takara Bio USA President and CEO Carol Lou to Retire, Succeeded by Andrew Farmer
(1d)
WuXi Biologics Drug Substance Manufacturing Facility Passes FDA Pre-License Inspection
(1d)
Securing Reliable U.S. Supply of Complex Oral Solid Dose Manufacturing
(1d)
Pharma Times
Pluripotent stem cell trial for Huntington’s disease
(2d)
Jascayd gains UK licence for treatment of pulmonary fibrosis
(2d)
Grünenthal receives FDA designations for tegacorat in Duchenne muscular dystrophy
(3d)
Compass Pathways reports six‑month data confirming durable profile of COMP360
(3d)
Ferrer and Prilenia begin confirmatory study of pridopidine in Huntington’s disease
(3d)
Medcity News
What Is AI Getting Right — and Wrong — in Healthcare’s Revenue Cycle?
(3w)
KFF: Insurer Participation in ACA Marketplaces Is Down
(3w)
FDA Reversal on uniQure Gene Therapy Is Another Sign of Renewed Regulatory Flexibility
(3w)
Combined GI Procedures Are Becoming Routine – AI Can Help Address the Gap in Upper GI Quality Standards
(3w)
The Human Behind the Machine: Why Healthcare Must Resist the Rush To Automate
(3w)
Chemical & Engineering News
Memory Lane: Cultivating a right to science education
(12h)
Policy Watch: FDA rejects petition to set PFAS limits in certain foods
(14h)
Chemists get twice the reactivity from a single substitution handle
(16h)
Meet the 2026 CAS Future Leaders
(19h)
What the nose knows
(19h)
The Pharma Letter
Padcev-Keytruda wins broader FDA approval in bladder cancer
(13h)
FDA thumbs up for Sanofi’s subcutaneous Sarclisa Escena
(17h)
Hansoh reports positive Phase III China data for GSK-partnered Ris-Rez in small cell lung cancer
(17h)
Chronic hepatitis C cases set to edge higher across major markets through 2035, says GlobalData
(17h)
NMPA reviews QMS for regulation of vaccine and drug GMP compliance
(18h)
Targeted Oncology
FDA Accepts NDA for Varegacestat in Desmoid Tumors
(2d)
Oral CELMoD Golcadomide Advances in Relapsed FL
(2d)
Implementing a Bispecific Antibody Program in Community Oncology—Insights From the American Oncology Network
(2d)
The Evolution of Treatment Goals in Immune Thrombocytopenia
(2d)
After the First TKI Fails: Sequencing Challenges in ROS1-Positive NSCLC
(3d)
MedWatch
Mikael Dolsten takes chair at AI company BenchSci after withdrawing from Novo Nordisk board race
(19h)
After years of delays: MagCath's female catheter greenlighted for sale in Europe
(20h)
Biotech CEO on new Novo Nordisk partnership: “This could be big”
(20h)
Danish Copli acquired by US company to help pharma firms avoid regulatory violations
(21h)
FDA criticizes Lundbeck: Websites are “false or misleading”
(21h)
In The Pipeline
Chemical Onshoring of All Kinds
(1d)
Turning Down the Refinery Heat
(2d)
A Telomerase Inhibitor Revealed
(3d)
Behold the SpudCell
(4d)
Don't Minimize the Side Effects
(1w)
Pharmaphorum
Non-profit DNDi preps phase 3 trials for dengue antibody
(21h)
Bausch + Lomb drug fails in glaucoma, but a new use beckons
(22h)
Roche abandons two Huntington's drug candidates
(23h)
Bayer gets €3bn from Apollo for contraceptives unit stake
(1d)
Moderna's mResvia gets shot in the arm from EU contract
(1d)
Drug Discovery Weekly
Wegovy pill could help patients lose 17% body weight
(3w)
How AskBio is pioneering ‘transformative genetic therapies’ in Parkinson’s disease
(3w)
Webinar: Learn how to accelerate the early stages of drug discovery
(3w)
Therapy enables 89% survival rate in myeloma patients
(3w)
Ulcerative colitis treatment shows best-in-class potential
(3w)
HIT Consultant
Health Payers Have Invested in Modern Data Infrastructure. Access Control Hasn’t Kept Up.
(1d)
The Technology Gap Holding Provider-Sponsored Health Plans Back
(1d)
Grounding Clinical AI in Evidence: The Critical Role of Human Oversight and Continuous Validation
(1d)
Beyond the Screen: How Telepsychiatry Must Evolve in theEra of Interventional Psychiatry
(1d)
Scaling Enterprise Imaging: IT Lessons from Digital Pathology
(1d)
Insights: Pink Sheet
US FDA Proposes One Registration For Distributed Drug Manufacturing Networks
(10h)
US FDA Hiring Binge: CDER, CBER Report Q3 Bump, First Since Trump Administration Cuts
(12h)
Unpause? US FDA Posts 14 New CRLs After Temporary Halt
(15h)
Pink Sheet Podcast: Complete Response Letter And DTC Ad Regulations, Potential US FDA Reorg
(15h)
Recent And Upcoming US FDA Advisory Committee Meetings
(15h)
BioXconomy
Germany doubles pharma rebates to curb costs
(16h)
Legislative changes alter GTN landscape
(20h)
Sandoz launches direct-to-patient drug platform
(21h)
Leo Cancer Care lands $65m Series D to bring upright proton platform to underserved communities
(23h)
Realizing Integrated Planning and Gross-to-Net
(1d)
BioCentury
With first clinical data due next year, Scribe to test IPO market: Finance Report
(7h)
FDA resumes CRL releases, citing ‘commitment to transparency’
(8h)
Perspective — siRNAs are better than ASOs
(9h)
2Q26 Wrap: Income inequality
(9h)
Can M&A momentum carry biotech through year-end?
(10h)
SCRIP
Gilead’s Biggest Buys Balance Drug Candidate Needs With Platform Desires
(11h)
Roche Pulls Plug On Two Antisense Oligonucleotide Programs In Huntington’s
(11h)
Pharma At The Midyear: Taking Stock Of Financial Forecasts
(11h)
LEO Reports Phase II Pediatric Data As Tralokinumab Advances Through Phase III
(17h)
Bayer Break-Up Rumors Revived After €3bn Apollo Pact
(19h)